We are pleased to announce that Regensight will be the Main Sponsor of the World Congress on Keratoconus 2025, which will be held in Athens, Greece, from June 12 to 14. This prestigious event brings together the world’s leading experts to discuss the l ...
We are thrilled to announce that RitSight, our 0.22% riboflavin ophthalmic solution for corneal cross-linking, has been granted the CE Certificate in conformity with the Medical Device Regulation (MDR)! This certification marks a significant step forward ...
We are thrilled to announce an important milestone in our Teracor project! At the Intermediate Progress Report of the project funded with European funds by Lazio Innova, we have completed over 60% of the planned objectives! The Teracor project a ...
🔬 Breakthrough Advancement in Clinical Research for the Treatment of Keratoconus 🔬 We are excited to announce the publication of the ARGO clinical trial validating theranostics technology for the precision, predictive and personalized treatment of ke ...
Regensight will join the most important and awaited International Annual Conference in corneal and cataract surgery organized by ESCRS in Barcelona (https://congress.escrs.org/) on 6-10 September 2024. With validation of theranostics in the randomized mu ...
We are excited to announce the publication of a new scientific article, entitled "Spatial targeted delivery of riboflavin with a controlled corneal iontophoresis delivery system in theranostic-guided UV-A light photo-therapy", in the prestigious Journal ...
Glad to share the outcomes of a recent manuscript, published on Graefe’s Archive for Clinical & Experimental Ophthalmology, assessing the performance of several clinically available riboflavin ophthalmic formulations for corneal cross-linking. The ...
The project n. A0613-2023-077528 of Regensight srl was granted by Lazio Innova in response to the "RSI Competitive Repositioning" Public Notice, FESR Program 2021-2027 referred to in Det. n. G18823 dated 12/28/2022 and granted with the Det. n. G15206 date ...
The Regensight's Theranostics (a new paradigm of therapy guided by diagnostics), is going to halt keratoconus progression with certainty. Keratoconus is primary cause of corneal transplant in young adults worldwide (prevalence: 1% - 2%, about 100 mil ...
The Regensight team has been an active part of The European Society of Cataract and Refractive Surgery (ESCRS) International Conference, which was held in Vienna from 8 to 11 September 2023.At the startup's stand, the Team has allowed the eye surgeons to ...
